Avacincaptad Pegol

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Idiopathic Polypoidal Choroidal Vasculopathy

Conditions

Idiopathic Polypoidal Choroidal Vasculopathy

Trial Timeline

Mar 12, 2015 → Oct 23, 2015

NCT ID

NCT02397954

About Avacincaptad Pegol

Avacincaptad Pegol is a phase 2 stage product being developed by Astellas Pharma for Idiopathic Polypoidal Choroidal Vasculopathy. The current trial status is completed. This product is registered under clinical trial identifier NCT02397954. Target conditions include Idiopathic Polypoidal Choroidal Vasculopathy.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06970665	Approved	Recruiting	Jul 8, 2025	Jun 30, 2027	Geographic Atrophy
NCT05536297	Phase 3	Completed	Sep 26, 2022	Apr 10, 2025	Geographic Atrophy
NCT02686658	Phase 2/3	Completed	Dec 15, 2015	Apr 23, 2020	Geographic Atrophy
NCT02397954	Phase 2	Completed	Mar 12, 2015	Oct 23, 2015	Idiopathic Polypoidal Choroidal Vasculopathy
NCT00950638	Phase 1	Completed	Jul 16, 2009	Mar 24, 2011	Dry Age-Related Macular Degeneration
NCT00709527	Phase 1	Completed	Oct 16, 2008	Dec 30, 2009	Neovascular Age-Related Macular Degeneration

Competing Products

20 competing products in Idiopathic Polypoidal Choroidal Vasculopathy

See all competitors

Product	Company	Stage	Hype Score
KPL-716 + Placebo	Kiniksa Pharmaceuticals	Phase 2	47
Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) + Placebo	Rein Therapeutics	Phase 1	25
LTI-03 + Placebo	Rein Therapeutics	Phase 1	25
LTI-03 + Placebo	Rein Therapeutics	Phase 2	44
Tirzepatide + Tirzepatide Placebo	Eli Lilly	Approved	85
MRA(Tocilizumab)	Chugai Pharmaceutical	Phase 3	77
MRA(Tocilizumab) + placebo	Chugai Pharmaceutical	Phase 3	77
MRA(Tocilizumab)	Chugai Pharmaceutical	Phase 3	77
MRA(Tocilizumab)	Chugai Pharmaceutical	Phase 3	77
Zimura + Eylea	Astellas Pharma	Phase 2	52
Rituximab + cyclosporine	Sun Pharmaceutical	Phase 3	77
E5501	Eisai	Phase 1	33
E5501 + Drug: E5501	Eisai	Phase 1	33
E5501 40 mg 2 x 20-mg tablets, orally, fasted + E5501 40 mg 2 x 20-mg tablets, orally, with food + E5501 40mg 2 x 20-mg tablets, orally, fasted + E5501 40 mg 2 x 20-mg tablets, orally, with food	Eisai	Phase 1	33
Eltrombopag + Avatrombopag + Standard of care	Eisai	Phase 3	77
Placebo + Avatrombopag tablets	Eisai	Phase 2	52
Perampanel	Eisai	Pre-clinical	23
Blinded (placebo) + Open Label (Avatrombopag tablets) + Blinded (Avatrombopoag tablets)	Eisai	Phase 2	52
Istradefylline 20 mg or 40 mg	Kyowa Kirin	Phase 3	77
10-mg dose of E5501 2G tablet + 10-mg dose of E5501 cyclodextrin oral solution + 10-mg dose of E5501-P21% powder + 10-mg dose of E5501 lipid-based oral	Eisai	Phase 1	33

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved

micafungin + voriconazoleApproved

mirabegron + solifenacinApproved

Zolpidem (Myslee®) + placeboApproved

TacrolimusApproved